{"filing":{"accession_number":"0001493152-26-036112","cik":"0001725430","ticker":"INBS","company_name":"INTELLIGENT BIO SOLUTIONS INC.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315226036112/form8-k.htm"},"events":[{"id":24880,"run_id":22555,"accession_number":"0001493152-26-036112","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses completion of a Usability Study for the Intelligent Fingerprinting Drug Screening System, which supports the company's FDA 510(k) submission for U.S. market clearance. This is a material operational and regulatory milestone—the study demonstrates the system can be used by non-specialist operators and represents progress toward entry into the multi-billion-dollar U.S. drug screening market. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's regulatory pathway and commercialization prospects.","company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":25572,"accession_number":"0001493152-26-036112","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses completion of a Usability Study for the Intelligent Fingerprinting Drug Screening System, which supports the company's FDA 510(k) submission for U.S. market clearance. This is a material operational and regulatory milestone—the study demonstrates the system can be used by non-specialist operators and represents progress toward entry into the multi-billion-dollar U.S. drug screening market. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's regulatory pathway and commercialization prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:32:24.454504+00:00","company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","filing_date":"2026-08-05"}]}